Owner Scorecard


← Japan catalog ← 4503 Manual 4507 → ← 4503 Pharmaceuticals 4507 →

4506 · Sumitomo Pharma

Pharma Asset-light compounder IFRS
Latest filing: FY2026 annual securities report (有価証券報告書) · EDINET

This is a quantitative scorecard. The numbers below are read directly from Sumitomo Pharma’s EDINET filing, in yen. The Japanese-language narrative, what the business does, its risks, what changed this year, is not machine-read here, so we do not paraphrase it. Find it on EDINET (code 4506) →

I

The record

What the business has done across the cycle, read straight from the EDINET filing: the multi-year record, and the walk from reported profit to the cash an owner could take out.

The record, 2017–2026

realized figures from each filing · older years to the left
2017’172018’182019’192020’202021’212022’222023’232024’242025’252026’26
Income statement
¥408.4B¥466.8B¥459.3B¥482.7B¥516.0B¥560.0B¥555.5B¥314.6B¥398.8B¥453.3BRevenueRevenue
73%73%62%57%Gross marginGross mgn
32%37%45%36%SG&A / revenueSG&A/rev
8%7%7%7%R&D / revenueR&D/rev
¥89.8B¥88.2B¥57.9B¥83.2B¥71.2B¥60.2B(¥77.0B)(¥354.9B)¥28.8B¥107.3BOperating incomeOp. inc.
22.0%18.9%12.6%17.2%13.8%10.8%−13.9%−112.8%7.2%23.7%Operating marginOp. mgn
¥31.3B¥53.4B¥48.6B¥40.8B¥56.2B¥56.4B(¥74.5B)(¥315.0B)¥23.6B¥106.9BNet incomeNet inc.
Cash flow & returns
¥19.1B¥93.4B¥48.7B¥46.1B¥135.6B¥31.2B¥11.9B(¥241.9B)¥16.5B¥71.7BOperating cash flowOp. cash
¥12.9B¥14.0B¥17.4B¥22.7B¥38.3B¥41.3B¥37.8B¥25.6B¥20.8BDepreciationDeprec.
(¥12.2B)¥27.1B(¥13.9B)(¥12.0B)¥56.7B(¥63.5B)¥45.2B¥35.3B(¥32.7B)(¥55.9B)Working capital & otherWC & other
¥5.1B¥9.3B¥7.7B¥6.0B¥7.3B¥8.5B¥10.8B¥8.5B¥4.6BCapexCapex
1.1%2.0%1.6%1.2%1.3%1.5%3.4%2.1%1.0%Capex / revenueCapex/rev
¥88.3B¥39.4B¥38.4B¥129.6B¥23.9B¥3.5B(¥252.7B)¥8.0B¥67.1BOwner earningsOwner earn.
18.9%8.6%8.0%25.1%4.3%0.6%−80.3%2.0%14.8%Owner earnings marginOE mgn
¥88.3B¥39.4B¥38.4B¥129.6B¥23.9B¥3.5B(¥252.7B)¥8.0B¥67.1BFree cash flowFCF
18.9%8.6%8.0%25.1%4.3%0.6%−80.3%2.0%14.8%Free cash flow marginFCF mgn
¥7.2B¥7.9B¥11.1B¥13.1B¥11.1B¥11.1B¥11.1B¥2.8B¥3M¥2MDividends paidDiv. paid
¥3M¥2M¥6M¥3M¥2M¥2M¥1M¥0¥0¥2MBuybacksBuybacks
16%20%12%14%9%7%-12%-108%6%20%ROICROIC
8%12%10%8%10%9%-18%-202%14%37%Return on equityROE
6%10%8%5%8%7%−21%−204%14%37%Retained to equityRetained/eq
Balance sheet
¥40.8B¥147.8B¥137.3B¥101.7B¥193.7B¥203.0B¥143.5B¥29.0B¥23.1B¥44.3BCash & investmentsCash+inv
¥74.1B¥113.0B¥118.8B¥134.5B¥135.9B¥151.4B¥95.9B¥81.0B¥74.8B¥131.4BReceivablesReceiv.
¥33.8B¥34.2B¥35.0B¥45.7B¥49.6B¥40.3B¥39.4B¥43.7B¥37.7B¥48.4BInventoryInvent.
¥58.7B¥49.2B¥62.3B¥64.6B¥46.2B¥52.1B¥67.7B¥38.5B¥56.7BAccounts payablePayables
¥107.9B¥88.5B¥104.6B¥118.0B¥120.8B¥145.5B¥83.2B¥57.0B¥74.0B¥123.1BOperating working capitalOper. WC
¥246.1B¥348.6B¥373.3B¥364.1B¥459.8B¥499.5B¥381.9B¥269.6B¥253.2B¥279.3BCurrent assetsCur. assets
¥101.1B¥68.8B¥56.8B¥336.9B¥82.9B¥77.6B¥151.6B¥365.3B¥85.8B¥129.1BCurrent liabilitiesCur. liab.
2.4×5.1×6.6×1.1×5.5×6.4×2.5×0.7×3.0×2.2×Current ratioCurr. ratio
¥95.1B¥99.3B¥173.5B¥176.5B¥195.1B¥209.4B¥199.8B¥197.4B¥211.1BGoodwillGoodwill
¥779.1B¥809.7B¥834.7B¥1.26T¥1.31T¥1.31T¥1.13T¥907.5B¥742.6B¥804.6BTotal assetsAssets
¥68.0B¥47.4B¥30.9B¥25.0B¥263.9B¥244.0B¥244.1B¥133.4B¥259.0B¥179.1BTotal debtDebt
¥27.2B(¥100.4B)(¥106.4B)(¥76.7B)¥70.2B¥41.0B¥100.7B¥104.3B¥235.9B¥134.7BNet debt / (cash)Net debt
109.2×15.4×279.6×29.1×27.5×19.7×-24.4×-83.0×2.1×10.5×Interest coverageInt. cov.
¥412.3B¥452.7B¥498.1B¥532.7B¥580.6B¥607.9B¥406.7B¥156.1B¥169.5B¥292.5BShareholders’ equityEquity
Per share
398M398M398M398M398M398M398M398M398M398MShares out (diluted)Shares
¥1026.28¥1173.25¥1154.23¥1213.20¥1296.69¥1407.48¥1396.19¥790.55¥1002.34¥1139.22Revenue / shareRev/sh
¥78.70¥134.33¥122.21¥102.42¥141.29¥141.78¥-187.26¥-791.58¥59.40¥268.57EPS (diluted)EPS
¥221.89¥99.14¥96.52¥325.59¥60.05¥8.72¥-634.99¥20.11¥168.65Owner earnings / shareOE/sh
¥221.89¥99.14¥96.52¥325.59¥60.05¥8.72¥-634.99¥20.11¥168.65Free cash flow / shareFCF/sh
¥17.97¥19.96¥27.95¥32.94¥27.95¥27.96¥27.96¥7.02¥0.01¥0.01Dividends / shareDiv/sh
¥12.89¥23.28¥19.41¥15.20¥18.46¥21.28¥27.07¥21.36¥11.58Cap. spending / shareCapex/sh
¥1036.11¥1137.78¥1251.92¥1338.70¥1459.09¥1527.74¥1022.24¥392.22¥425.93¥735.03Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+1.2%/yr−2.6%/yr
Owner earnings / share−3.4%/yr (8-yr)−12.3%/yr
EPS+14.6%/yr+13.7%/yr
Dividends / share−59.7%/yr−82.2%/yr
Capital spending / share−1.3%/yr (8-yr)−5.3%/yr
Book value / share−3.7%/yr−12.8%/yr

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2026 the business reported ¥106.9B of profit but ¥67.1B of owner earnings: ¥39.8B less than the profit line, taken out by capital spending and the timing of cash.

Reported net income¥106.9B
Owner earnings¥67.1B · 15% of revenue
FY2026FY2025FY2024FY2023FY2022
Reported net income¥106.9B¥23.6B(¥315.0B)(¥74.5B)¥56.4B
Depreciation & amortizationnon-cash charge added back+¥20.8B+¥25.6B+¥37.8B+¥41.3B+¥38.3B
Working capital & othertiming of cash in and out, other non-cash items−¥55.9B−¥32.7B+¥35.3B+¥45.2B−¥63.5B
Cash from operations¥71.7B¥16.5B(¥241.9B)¥11.9B¥31.2B
Capital expenditurecash put back in to keep running and to grow−¥4.6B−¥8.5B−¥10.8B−¥8.5B−¥7.3B
Owner earnings¥67.1B¥8.0B(¥252.7B)¥3.5B¥23.9B
Owner-earnings marginowner earnings ÷ revenue15%2%-80%1%4%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .

Much of fiscal 2026's profit didn't arrive as operating cash; it sits in “working capital & other” above. That can be a real inventory or timing swing, or profit that doesn't run through operating cash at all: a heavy tax year, equity-method earnings, or investment income booked through investing. For a year like this, owner earnings understates the cash earned; the full cash-flow statement carries the rest.

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

II

Quality & stewardship

Returns, the balance sheet, and stewardship. The same checks the US pages run, in yen.

Owner’s Scorecard

FY2026 Annual securities report · source on EDINET →

Will it survive?

  • Comfortable
    Operating income ¥107.3B ÷ interest expense ¥10.2B
    What this means

    Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.

  • How heavy is the debt, net of cash? ¥134.7B · 1.3× operating profit
    Modest net debt
    Cash ¥44.3B − debt ¥179.1B
    What this means

    Netting ¥44.3B of cash and short-term investments against ¥179.1B of debt leaves ¥134.7B owed, about 1.3× a year's operating profit (1.7× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Long (60+ days)
    DSO 106 + DIO 90 − DPO 105 days
    What this means

    Days cash is tied up between paying suppliers and collecting from customers. Lower is better; a long cycle means growth itself eats cash.

Is it a good business?

  • Solid through the cycle
    10-yr median, range -108%–20%; 20% latest = NOPAT ¥84.8B ÷ invested capital ¥427.2B
    Industry peers: median 18%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran 20% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • Solid through the cycle
    9-yr median margin, range -80%–25%; latest ¥67.1B = operating cash ¥71.7B − maintenance capex ¥4.6B
    Industry peers: median 11%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 15% of revenue this year, a 8% median across 9 years.

  • Mostly cash-backed
    Cash from ops ¥71.7B ÷ net income ¥106.9B
    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Reinvests most of it
    Dividends + buybacks ¥4M ÷ Owner Earnings ¥67.1B
    What this means

    Of ¥67.1B Owner Earnings, ¥4M (0%) went back to shareholders, ¥2M dividends, ¥2M buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.

  • Investing or harvesting? 0.22×
    Harvesting
    Capex ¥4.6B ÷ depreciation ¥20.8B
    What this means

    Descriptive, not a grade. Above ~1× means investing faster than assets wear out (growth, or, sustained for years, today's earnings carrying less depreciation than tomorrow's will). Below means spending less than it's wearing out (efficiency, or a melting asset base). The ratio won't tell you which; the filings will.

Durability & moat, 2017–2026

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 8 of 10
    What this means

    Lost money in 2 year(s), look at what happened there before trusting the average.

  • Return on capital ≥ 15% 3 of 10 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin 18% → −27% (3-yr avg ends)
    What this means

    The recent-years average (−27%) sits below the early years (18%), but the latest year (24%) is back near the early level: a cyclical trough dragging the window down, not a one-way slide. The through-cycle median is 13% — read it across the cycle, not on the dip.

  • Reinvestment, incremental ROIC returns capital
    What this means

    The capital base barely grew: this business returns cash through dividends and buybacks rather than reinvesting. Judge it on the cash returned, not on compounding.

  • Owner earnings growth −6%/yr
    What this means

    Owner earnings shrank about 6% a year over the record.

  • Worst year 2024 · −112.8% op. margin
    What this means

    Operations went underwater in 2024, understand why before trusting the good years.

  • Share count +0.0%/yr
    What this means

    Roughly flat share count, little dilution, little buyback.

  • Dividend record paid
    What this means

    Paid a dividend in 10 of the years on record.

All figures as filed; the source filing is linked above.

How the cash was used, 2018–2026

Over the record, the business generated ¥213.4B of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.

  • Reinvested¥67.9B · 32%
  • Dividends¥68.3B · 32%
  • Buybacks¥18M · 0%
  • Retained (debt / cash)¥77.1B · 36%
  • Returned to owners¥68.4B

    47% of the owner earnings the business produced over the span, ¥68.3B as dividends and ¥18M as buybacks.

  • Source of fundingOperating cash

    Operating cash covered reinvestment and returns; over the span debt rose ¥131.7B and cash and short-term investments fell ¥103.5B.

  • Average price paid for buybacks

    Buybacks ran ¥18M over the span, but the filings don't tag the share count needed to deduce the average price paid.

  • Net change in share count0.0%

    The diluted count barely moved (398M to 398M): buybacks roughly offset the stock issued to staff.

  • Dividend record¥0.01/sh

    Paid in 9 of the years on record, the per-share dividend shrinking about 65% a year. It was cut at least once along the way.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Inverting the record

Invert: instead of why Sumitomo Pharma is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2017–2026.

2 of the 5 tests turned up something to look into; the other 3 came back clean.

  • Look hereDid debt outgrow the business?¥68.0B → ¥179.1B

    Debt rose from ¥68.0B to ¥179.1B while owner earnings went from about ¥55.4B to (¥59.2B): the borrowing grew and the earnings that would carry it are not there now. Debt raised for buybacks or deals rather than growth is the kind that bites in a downturn.

  • Look hereDid receivables and inventory outpace sales?26% → 40% of sales

    Receivables and inventory grew from ¥107.9B to ¥179.8B while revenue grew 11%: working capital is climbing faster than sales (26% of revenue then, 40% now). That can mean customers paying slower, stock building up, or revenue pulled forward. The filing's cash-flow and receivables notes say which.

And these came back clean
  • Is it less profitable than it was?
  • Did the share count rise anyway?
  • Did reported profit become cash?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

III

The price

What a price would have to assume, set against the record above.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Sumitomo Pharma has delivered.

Sumitomo Pharma’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.

¥

Through the cycle, Sumitomo Pharma earns about ¥36.1B on its 8.0% median owner-earnings margin. This year’s 14.8% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.

Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’22→’26+29%/yr
Owner-earnings growth · ’18→’26−6%/yr
Owner-earnings yield
P/E (3-yr earnings ’24–’26)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Owner earnings ¥67.1B on 398M diluted shares; net debt ¥134.7B. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Figures from EDINET, the Financial Services Agency’s disclosure system, the same kind of filing the US pages draw from EDGAR. A separate pool: these names never pass through the US industry classifier.

Manual order: ← 4503 its page in the Manual 4507 →

Industry order: ← 4503 the Pharmaceuticals chapter 4507 →